Published in Clin Cancer Res on January 01, 2009
A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma. J Transl Med (2011) 2.86
Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4. J Exp Med (2013) 2.13
The oncogenic BRAF kinase inhibitor PLX4032/RG7204 does not affect the viability or function of human lymphocytes across a wide range of concentrations. Clin Cancer Res (2010) 2.02
Anti-CTLA-4 antibody therapy: immune monitoring during clinical development of a novel immunotherapy. Semin Oncol (2010) 1.98
Dendritic cell vaccination combined with CTLA4 blockade in patients with metastatic melanoma. Clin Cancer Res (2009) 1.81
CTLA4 blockade broadens the peripheral T-cell receptor repertoire. Clin Cancer Res (2014) 1.66
Long term survival with cytotoxic T lymphocyte-associated antigen 4 blockade using tremelimumab. Eur J Cancer (2015) 1.53
CTLA4 blockade induces frequent tumor infiltration by activated lymphocytes regardless of clinical responses in humans. Clin Cancer Res (2011) 1.42
CTLA4 blockade increases Th17 cells in patients with metastatic melanoma. J Transl Med (2009) 1.28
New challenges in endpoints for drug development in advanced melanoma. Clin Cancer Res (2011) 1.12
Modulation of cell signaling networks after CTLA4 blockade in patients with metastatic melanoma. PLoS One (2010) 1.09
Ipilimumab, vemurafenib, dabrafenib, and trametinib: synergistic competitors in the clinical management of BRAF mutant malignant melanoma. Oncologist (2013) 1.08
Biomarkers on melanoma patient T cells associated with ipilimumab treatment. J Transl Med (2012) 1.04
Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25. Cell Res (2015) 1.02
Enhancement of anti-tumor immunity through local modulation of CTLA-4 and GITR by dendritic cells. Eur J Immunol (2011) 0.94
Indoleamine 2,3-dioxygenase activity and clinical outcome following induction chemotherapy and concurrent chemoradiation in Stage III non-small cell lung cancer. Oncoimmunology (2013) 0.94
T cells in the human metastatic melanoma microenvironment express site-specific homing receptors and retention integrins. Int J Cancer (2014) 0.93
Successful treatment of metastatic melanoma by adoptive transfer of blood-derived polyclonal tumor-specific CD4+ and CD8+ T cells in combination with low-dose interferon-alpha. Cancer Immunol Immunother (2011) 0.92
The role of indoleamine 2, 3-dioxygenase in lepromatous leprosy immunosuppression. Clin Exp Immunol (2011) 0.92
Safety profile and pharmacokinetic analyses of the anti-CTLA4 antibody tremelimumab administered as a one hour infusion. J Transl Med (2012) 0.87
Interdependent IL-7 and IFN-γ signalling in T-cell controls tumour eradication by combined α-CTLA-4+α-PD-1 therapy. Nat Commun (2016) 0.87
Multicenter phase II study of matured dendritic cells pulsed with melanoma cell line lysates in patients with advanced melanoma. J Transl Med (2010) 0.87
Anti-cytotoxic T lymphocyte antigen-4 antibodies in melanoma. Clin Cosmet Investig Dermatol (2013) 0.85
Targeting myeloid-derived suppressor cells with colony stimulating factor-1 receptor blockade can reverse immune resistance to immunotherapy in indoleamine 2,3-dioxygenase-expressing tumors. EBioMedicine (2016) 0.83
Regulatory T Cells in the Tumor Microenvironment and Cancer Progression: Role and Therapeutic Targeting. Vaccines (Basel) (2016) 0.82
Blockade of cytotoxic T-lymphocyte antigen-4 as a new therapeutic approach for advanced melanoma. Expert Opin Pharmacother (2011) 0.80
Modulation of CTLA-4 and GITR for cancer immunotherapy. Curr Top Microbiol Immunol (2011) 0.80
Adoptive TIL transfer in the adjuvant setting for melanoma: long-term patient survival. J Immunol Res (2014) 0.80
Tissue biomarkers in melanoma patients treated with TIL. PLoS One (2012) 0.79
Tremelimumab: research and clinical development. Onco Targets Ther (2016) 0.78
Human melanomas and ovarian cancers overexpressing mechanical barrier molecule genes lack immune signatures and have increased patient mortality risk. Oncoimmunology (2016) 0.77
Ipilimumab reshapes T cell memory subsets in melanoma patients with clinical response. Oncoimmunology (2016) 0.75
[Stable disease or complete response? : A critical evaluation of the radiologic response to immune checkpoint blockade in advanced melanoma]. Hautarzt (2017) 0.75
Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol (2009) 23.08
Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med (2006) 15.64
Final trial report of sentinel-node biopsy versus nodal observation in melanoma. N Engl J Med (2014) 10.69
American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol (2005) 8.56
Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032. J Transl Med (2010) 5.57
Exome sequencing-based copy-number variation and loss of heterozygosity detection: ExomeCNV. Bioinformatics (2011) 5.45
Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol (2013) 5.36
Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. J Clin Oncol (2005) 4.77
Sentinel node biopsy for early-stage melanoma: accuracy and morbidity in MSLT-I, an international multicenter trial. Ann Surg (2005) 3.80
Do we need a different set of response assessment criteria for tumor immunotherapy? Clin Cancer Res (2009) 3.01
Immunohistochemical characteristics of melanoma. J Cutan Pathol (2008) 3.00
Current developments in cancer vaccines and cellular immunotherapy. J Clin Oncol (2003) 2.87
Darbepoetin alpha for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study. J Clin Oncol (2008) 2.60
Phase I/II trial of tremelimumab in patients with metastatic melanoma. J Clin Oncol (2009) 2.53
BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors. Cancer Discov (2012) 2.48
Differential effects of prostaglandin derived from omega-6 and omega-3 polyunsaturated fatty acids on COX-2 expression and IL-6 secretion. Proc Natl Acad Sci U S A (2003) 2.40
Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases. J Clin Oncol (2010) 2.30
Phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma. Clin Cancer Res (2010) 2.20
Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy. Cancer (2002) 2.17
The oncogenic BRAF kinase inhibitor PLX4032/RG7204 does not affect the viability or function of human lymphocytes across a wide range of concentrations. Clin Cancer Res (2010) 2.02
Tremelimumab (CP-675,206), a cytotoxic T lymphocyte associated antigen 4 blocking monoclonal antibody in clinical development for patients with cancer. Oncologist (2007) 1.93
Metastasectomy for distant metastatic melanoma: analysis of data from the first Multicenter Selective Lymphadenectomy Trial (MSLT-I). Ann Surg Oncol (2012) 1.92
Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway. PLoS One (2011) 1.89
Determinant spreading associated with clinical response in dendritic cell-based immunotherapy for malignant melanoma. Clin Cancer Res (2003) 1.83
Dendritic cell vaccination combined with CTLA4 blockade in patients with metastatic melanoma. Clin Cancer Res (2009) 1.81
Prognostic significance of mitotic rate in localized primary cutaneous melanoma: an analysis of patients in the multi-institutional American Joint Committee on Cancer melanoma staging database. J Clin Oncol (2011) 1.78
Pooled analysis of individual patient-level data from all randomized, double-blind, placebo-controlled trials of darbepoetin alfa in the treatment of patients with chemotherapy-induced anemia. J Clin Oncol (2009) 1.77
EANM-EORTC general recommendations for sentinel node diagnostics in melanoma. Eur J Nucl Med Mol Imaging (2009) 1.68
Multifunctional T-cell analyses to study response and progression in adoptive cell transfer immunotherapy. Cancer Discov (2013) 1.68
CTLA4 blockade broadens the peripheral T-cell receptor repertoire. Clin Cancer Res (2014) 1.66
PTEN loss accelerates KrasG12D-induced pancreatic cancer development. Cancer Res (2010) 1.65
Metabolic control analysis in drug discovery and disease. Nat Biotechnol (2002) 1.59
A selective, Bayesian approach to intraoperative PTH monitoring. Ann Surg (2010) 1.56
Detailed analysis of immunologic effects of the cytotoxic T lymphocyte-associated antigen 4-blocking monoclonal antibody tremelimumab in peripheral blood of patients with melanoma. J Transl Med (2008) 1.56
Effect of altering dietary omega-6/omega-3 fatty acid ratios on prostate cancer membrane composition, cyclooxygenase-2, and prostaglandin E2. Clin Cancer Res (2006) 1.50
Pharmacodynamic characterization of the efficacy signals due to selective BRAF inhibition with PLX4032 in malignant melanoma. Neoplasia (2010) 1.48
A phase I/II trial testing immunization of hepatocellular carcinoma patients with dendritic cells pulsed with four alpha-fetoprotein peptides. Clin Cancer Res (2006) 1.48
Genetic and morphologic features for melanoma classification. Pigment Cell Melanoma Res (2010) 1.47
The effects of a high-fat meal on single-dose vemurafenib pharmacokinetics. J Clin Pharmacol (2014) 1.45
Ionizing radiation affects human MART-1 melanoma antigen processing and presentation by dendritic cells. J Immunol (2004) 1.44
CTLA4 blockade induces frequent tumor infiltration by activated lymphocytes regardless of clinical responses in humans. Clin Cancer Res (2011) 1.42
Role of dendritic cell phenotype, determinant spreading, and negative costimulatory blockade in dendritic cell-based melanoma immunotherapy. J Immunother (2004) 1.40
Radiation enhances regulatory T cell representation. Int J Radiat Oncol Biol Phys (2010) 1.39
Enhanced antitumor activity induced by adoptive T-cell transfer and adjunctive use of the histone deacetylase inhibitor LAQ824. Cancer Res (2009) 1.38
BRAF V600E inhibition in anaplastic thyroid cancer. N Engl J Med (2013) 1.38
Definition of an immunologic response using the major histocompatibility complex tetramer and enzyme-linked immunospot assays. Clin Cancer Res (2006) 1.37
Kinetic phases of distribution and tumor targeting by T cell receptor engineered lymphocytes inducing robust antitumor responses. Proc Natl Acad Sci U S A (2010) 1.36
Biologic and immunomodulatory events after CTLA-4 blockade with ticilimumab in patients with advanced malignant melanoma. Cancer (2006) 1.35
Immunomodulation by imiquimod in patients with high-risk primary melanoma. J Invest Dermatol (2011) 1.34
Combination therapy with vemurafenib (PLX4032/RG7204) and metformin in melanoma cell lines with distinct driver mutations. J Transl Med (2011) 1.33
Authors' response to a letter to the editor re: Sentinel node biopsy for early-stage melanoma. Ann Surg (2007) 1.32
CTLA4 blockade increases Th17 cells in patients with metastatic melanoma. J Transl Med (2009) 1.28
Phase II study of the anti-cytotoxic T-lymphocyte-associated antigen 4 monoclonal antibody, tremelimumab, in patients with refractory metastatic colorectal cancer. J Clin Oncol (2010) 1.24
T-cell responses to HLA-A*0201 immunodominant peptides derived from alpha-fetoprotein in patients with hepatocellular cancer. Clin Cancer Res (2003) 1.24
Determinant spreading and tumor responses after peptide-based cancer immunotherapy. Trends Immunol (2003) 1.23
Adenovirus MART-1-engineered autologous dendritic cell vaccine for metastatic melanoma. J Immunother (2008) 1.18
MicroRNA-21 in pancreatic ductal adenocarcinoma tumor-associated fibroblasts promotes metastasis. PLoS One (2013) 1.17
The rationale for sentinel-node biopsy in primary melanoma. Nat Clin Pract Oncol (2008) 1.17
Imaging of CTLA4 blockade-induced cell replication with (18)F-FLT PET in patients with advanced melanoma treated with tremelimumab. J Nucl Med (2010) 1.13
Quantitative analysis of melanoma-induced cytokine-mediated immunosuppression in melanoma sentinel nodes. Clin Cancer Res (2005) 1.11
Immune responses in the draining lymph nodes against cancer: implications for immunotherapy. Cancer Metastasis Rev (2006) 1.11
Cell intrinsic role of COX-2 in pancreatic cancer development. Mol Cancer Ther (2012) 1.10
Hidradenocarcinoma: a histological and immunohistochemical study. J Cutan Pathol (2006) 1.09
Modulation of cell signaling networks after CTLA4 blockade in patients with metastatic melanoma. PLoS One (2010) 1.09